IP Library Granted Patent US 7,390,880
Granted Patent B2
US 7,390,880 · App. 11/066,006 · Granted Jun 24, 2008

Soluble interleukin-1 receptor accessory molecule

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,390,880
App. No.
11/066,006
Granted
Jun 24, 2008
Kind
B2
Abstract

The present invention relates to a novel soluble IL-1 receptor accessory molecule (IL-1R AcM) protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human IL-1R AcM protein. IL-1R AcM polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Screening methods are futher provided for identifying agonist and antagonists of IL-1 signal transduction. The invention further relates to methods for treating physiologic and pathologic disease conditions with IL-1R AcM antagonists.

Claims (28)

1. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising amino acids −17 to 339 of SEQ ID NO:2;

(b) a polypeptide comprising amino acids 1 to 339 of sequence of SEQ ID NO:2;

(c) a polypeptide comprising the full-length IL-1R AcM polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97666; and

(d) a polypeptide comprising the mature IL-1R AcM polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97666.

2. The isolated polypeptide of claim 1 , wherein said polypeptide is (a).

3. The isolated polypeptide of claim 1 , wherein said polypeptide is (b).

4. The isolated polypeptide of claim 1 , wherein said polypeptide is (c).

5. The isolated polypeptide of claim 1 , wherein said polypeptide is (d).

6. The isolated polypeptide of claim 1 , wherein said polypeptide is glycosylated.

7. The isolated polypeptide of claim 1 , wherein said polypeptide is fused to a heterologous polypeptide.

8. An isolated polypeptide produced by a method comprising:

(a) expressing the polypeptide of claim 1 by a cell; and

(b) recovering said polypeptide.

9. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide consisting of amino acids −17 to 339 of SEQ ID NO:2;

(b) a polypeptide consisting of amino acids 1 to 339 of sequence of SEQ ID NO:2;

(c) a polypeptide consisting of the full-length IL-1R AcM polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97666; and

(d) a polypeptide consisting of the mature IL-1R AcM polypeptide encoded by the cDNA clone contained in ATCC Deposit No. 97666.

10. The isolated polypeptide of claim 9 , wherein said polypeptide is (a).

11. The isolated polypeptide of claim 9 , wherein said polypeptide is (b).

12. The isolated polypeptide of claim 9 , wherein said polypeptide is (c).

13. The isolated polypeptide of claim 9 , wherein said polypeptide is (d).

14. The isolated polypeptide of claim 9 , wherein said polypeptide is glycosylated.

15. The isolated polypeptide of claim 9 , wherein said polypeptide is fused to a heterologous polypeptide.

16. An isolated polypeptide produced by a method comprising:

(a) expressing the polypeptide of claim 9 by a cell; and

(b) recovering said polypeptide.

Assignments (2)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jul 18, 2023
From: MORGAN STANLEY & CO. INCORPORATED, AS COLLATERAL AGENT
To: EURO-PRO OPERATING LLC; EP MIDCO LLC; NEW EURO-PRO HOLDINGS LLC; EURO-PRO MANAGEMENT COMPANY
Reel/Frame 064310/0614 →
RELEASE OF SECURITY INTEREST Recorded Oct 13, 2017
From: BANK OF AMERICA, N.A.
To: SHARKNINJA OPERATING LLC
Reel/Frame 044207/0652 →